ID
22203
Beskrivning
A Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) on Cerebral Glucose Utilization and Cognition in Subjects With Mild to Moderate Alzheimer's Disease (AD) Medicine: rosiglitazone, Condition: Alzheimer's Disease, Phase: 2, Clinical Study ID: 49653/461, Sponsor: GSK Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00265148?term=NCT00265148&rank=1 This form is to be completed in/ after Screening Period 2, 1 Month +/- 3 Days, 6 Months +/- 1 week and 12 Months +/- 1 week.
Länk
https://clinicaltrials.gov/ct2/show/NCT00265148?term=NCT00265148&rank=1
Nyckelord
Versioner (1)
- 2017-05-22 2017-05-22 -
Uppladdad den
22 maj 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
FDG Pet Scan Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148
FDG Pet Scan Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148
Similar models
FDG Pet Scan Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148
C0808070 (UMLS CUI [1,2])
C0040223 (UMLS CUI [1,2])
C0449238 (UMLS CUI [1,2])
C0947611 (UMLS CUI [1,2])
C3174092 (UMLS CUI [1,2])
C0449468 (UMLS CUI [1,2])